Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Dow
Boehringer Ingelheim
Moodys
QuintilesIMS
McKesson
Daiichi Sankyo
UBS
Cipla

Generated: July 17, 2018

DrugPatentWatch Database Preview

Eptifibatide - Generic Drug Details

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

What are the generic drug sources for eptifibatide and what is the scope of eptifibatide patent protection?

Eptifibatide
is the generic ingredient in two branded drugs marketed by Accord Hlthcare, Akorn, Amneal Pharms, Aurobindo Pharma Ltd, Sagent Pharms, Teva Pharms Usa, and Schering, and is included in eight NDAs. Additional information is available in the individual branded drug profile pages.

There are fifteen drug master file entries for eptifibatide. Seven suppliers are listed for this compound.
Pharmacology for eptifibatide
Synonyms for eptifibatide
[(3R,11S,17S,20S,25aS)-11-(4-carbamimidamidobutyl)-3-carbamoyl-20-(1H-indol-3-ylmethyl)-1,9,12,15,18,21-hexaoxodocosahydro-7H-pyrrolo[2,1-g][1,2,5,8,11,14,17,20]dithiahexaazacyclotricosin-17-yl]acetic acid
[22-Carbamoyl-14-(4-guanidino-butyl)-5-(1H-indol-3-ylmethyl)-4,7,10,13,16,24-hexaoxo-docosahydro-19,20-dithia-3a,6,9,12,15,23-hexaaza-cyclopentacyclotricosen-8-yl]-acetic acid (C68-22, eptifibatide)
148031-34-9
157630-07-4
17-yl)acetic acid
188627-80-7
2-((3R,11S,17S,20S,25aS)-20-((1H-indol-3-yl)methyl)-3-carbamoyl-11-(4-guanidinobutyl)-1,9,12,15,18,21-hexaoxodocosahydro-7H-pyrrolo[2,1-g][1,2]dithia[5,8,11,14,17,20]hexaazacyclotricosin-
2-((3R,11S,17S,20S,25aS)-20-((1H-indol-3-yl)methyl)-3-carbamoyl-11-(4-guanidinobutyl)-1,9,12,15,18,21-hexaoxodocosahydro-7H-pyrrolo[2,1-g][1,2]dithia[5,8,11,14,17,20]hexaazacyclotricosin-17-yl)acetic acid
2-[(3R,11S,17S,20S,25aS)-11-(4-carbamimidamidobutyl)-3-carbamoyl-20-(indol-3-ylmethyl)-1,9,12,15,18,21-hexaoxo-docosahydro-1H-pyrrolo[2,1-g]1,2-dithia-5,8,11,14,17,20-hexaazacyclotricosan-17-yl]acetic acid
2-[(3R,11S,17S,20S,25aS)-3-carbamoyl-11-{4-[(diaminomethylidene)amino]butyl}-20-[(1H-indol-3-yl)methyl]-1,9,12,15,18,21-hexaoxo-docosahydro-1H-pyrrolo[2,1-g]1,2-dithia-5,8,11,14,17,20-hexaazacyclotricosan-17-yl]acetic acid
2-[(3S,6S,12S,20R,23S)-20-carbamoyl-12-[4-(diaminomethylideneamino)butyl]-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,22-hexaoxo-17,18-dithia-1,4,7,10,13,21-hexazabicyclo[21.3.0]hexacosan-6-yl]acetic acid
31E349
ABP000579
AC1L9MDI
AKOS015895205
AKOS025147403
BC657177
BDBM50092098
C-23554
C35H49N11O9S2
C68-22
CAS-188627-80-7
CC-27500
CHEBI:291902
CHEMBL1174
CS-2925
CZKPOZZJODAYPZ-LROMGURASA-N
D09ZIO
DSSTox_CID_26673
DSSTox_GSID_46673
DSSTox_RID_81810
DTXSID7046673
eftifibatide
Eptifibatide [INN:BAN]
Eptifibatide Accord (generic)
Eptifibatide Acetate
Eptifibatide(Integrilin)/
GTPL6585
HS-2011
HSDB 8313
HY-B0686
Integrelin
Integrilin
Integrilin (TN)
Intrifiban
L-Cysteinamide, N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophy-L-prolyl-, cyclic (1-6)-disulfide
L-Cysteinamide,N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-|A-aspartyl-L-tryptophyl-L-prolyl-, cyclic (1 inverted exclamation marku6)-disulfide
L-Cysteinamide,N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophy-L-propyl-,cyclic (1-6)-disulfide
LS-173318
MCULE-5698614065
MolPort-006-069-141
N(6)-amidino-N(2)-(3-mercaptopropionyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, cyclic(1-6)-disulfide
N(sup 6)-Amidino-N(sup 2)-(3-mercaptopropionyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, cyclic(1-6)-disulfide
NA8320J834
NCGC00167505-01
NCGC00263524-01
S(1),S(6)-cyclo[N(6)-carbamimidoyl-N(2)-(3-sulfanylpropanoyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide]
SB-1
Sch-60936
SCHEMBL15781
Tox21_112503
Tox21_112503_1
UNII-NA8320J834
V1343
Z2241982440
ZINC85536935

US Patents and Regulatory Information for eptifibatide

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Accord Hlthcare EPTIFIBATIDE eptifibatide INJECTABLE;INJECTION 205557-002 Nov 6, 2017 AP RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Teva Pharms Usa EPTIFIBATIDE eptifibatide INJECTABLE;INJECTION 090854-001 Jun 12, 2015 AP RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Aurobindo Pharma Ltd EPTIFIBATIDE eptifibatide INJECTABLE;INJECTION 206127-001 Dec 8, 2015 AP RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Amneal Pharms EPTIFIBATIDE eptifibatide INJECTABLE;INJECTION 205581-001 Dec 8, 2016 AP RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for eptifibatide

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Schering INTEGRILIN eptifibatide INJECTABLE;INJECTION 020718-001 May 18, 1998 ➤ Sign Up ➤ Sign Up
Schering INTEGRILIN eptifibatide INJECTABLE;INJECTION 020718-002 May 18, 1998 ➤ Sign Up ➤ Sign Up
Schering INTEGRILIN eptifibatide INJECTABLE;INJECTION 020718-001 May 18, 1998 ➤ Sign Up ➤ Sign Up
Schering INTEGRILIN eptifibatide INJECTABLE;INJECTION 020718-002 May 18, 1998 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Fish and Richardson
Boehringer Ingelheim
Covington
McKinsey
Cipla
Mallinckrodt
Merck
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.